Ivelin Georgiev

USPTO Granted Patents = 21 (Patent Applications = 17)

CIPO Patents = 1 (Patent Applications = 3)

EPO Patents = 3 (Patent Applications = 7)

Average Co-Inventor Count = 11.2

ph-index = 4

Forward Citations = 52(Granted Patents)

Location History:

Gaithersburg, MD (US) (2016 - 2018)
Nashville, TN (US) (2018 - 2024)

Company Filing History:

19 out of 3,539

The United States of America, As Represented by the Secretary, Department of Health and Human Services

patents

2 out of 1,153

Vanderbilt University

where one patent can have more than one assignee

Years Active: 2016-2025

Loading Chart...

21 patents (USPTO):Sort by Forward CitationsExplore Patents

1. 12416037 - Methods for identification of ligand-blocking antibodies and for determining antibody potency (2025-09-16),

2. 12331133 - Therapeutic antibodies for treating lung cancer (2025-06-17),

3. 12275758 - Prefusion RSV F proteins and their use (2025-04-14),

4. 12145968 - Recombinant HIV-1 envelope proteins and their use (2024-11-19),

5. 12043660 - 10E8 neutralizing antibody variants that bind to the MPER region of HIV-1 GP41 and their use (2024-07-23),

6. 11981707 - Prefusion RSV F proteins and their use (2024-05-14),

7. 11939356 - Self-assembling insect ferritin nanoparticles (2024-03-26),

8. 11878998 - Prefusion RSV F proteins and their use (2024-01-23),

9. 11459360 - Recombinant HIV-1 envelope proteins and their use (2022-10-04),

10. 11236152 - Neutralizing antibodies to HIV-1 GP41 and their use (2022-02-01),

11. 11174292 - Substitutions-modified prefusion RSV F proteins and their use (2021-11-16),

12. 11130785 - Prefusion RSV F proteins and their use (2021-09-28),

13. 10961283 - Self-assembling insect ferritin nanoparticles for display of co-assembled trimeric antigens (2021-03-30),

14. 10815295 - Broadly neutralizing HIV-1 antibodies that bind to the CD4-binding site of the envelope protein (2020-10-27),

15. 10400015 - Recombinant HIV-1 envelope proteins and their use (2019-09-03),

Title: Innovator Ivelin Stefanov Georgiev: Pioneering Solutions for RSV Infections

Introduction: Ivelin Stefanov Georgiev is a notable inventor based in Nashville, TN, United States. With a focus on medical innovations, he has made significant contributions to the field of virology, particularly in the fight against Respiratory Syncytial Virus (RSV).

Latest Patents: Georgiev holds one patent titled "Prefusion RSV F proteins and their use." This patent discloses important advancements concerning RSV antigens, specifically a recombinant RSV F protein that is stabilized in a prefusion conformation. Additionally, the patent includes nucleic acids that encode these antigens and methodologies for producing them. Notably, it outlines methods aimed at generating an immune response in subjects and offers potential treatment and prevention strategies for RSV infections through the administration of therapeutically effective amounts of the antigen.

Career Highlights: Ivelin Georgiev's career is highlighted by his work with the United States Department of Health and Human Services. His role emphasizes a commitment to public health and innovation in vaccine development, playing a pivotal part in enhancing the immune response against respiratory viruses.

Collaborations: Throughout his professional journey, Georgiev has likely collaborated with various health organizations and research institutions. These collaborations are essential for advancing his work on RSV and ensuring it reaches a broad audience for further development and application.

Conclusion: Ivelin Stefanov Georgiev stands as an inspiring example of modern inventors making strides in healthcare. His innovative work on RSV-related therapeutics demonstrates the critical importance of scientific research in combating viral infections. As the healthcare landscape evolves, innovators like Georgiev will continue to be instrumental in developing solutions that protect public health.

This text is generated by artificial intelligence and may not be accurate.